DelveInsight’s, “T Type Calcium Channel Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in T Type Calcium Channel Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
T Type Calcium Channel Antagonists: Overview
T-type calcium channels are low-voltage activated calcium channels. T-type calcium channels are predominantly found in neurons but have been found in other cells including cardiac myocytes, pacemaker cells, glial cells, fibroblasts, osteoblasts, retinal cells, and adrenocortical cells. These channels are known to play roles in the development, maintenance, and repair of these tissues but have also been implicated in disease when not properly regulated. T-type Ca2+ channel blockers are capable of interrupting certain pathological hypertrophic signaling pathways, including calcineurin-mediated nuclear factor of activated T cells–3 activation. Trimethadione (TMO) is a T-type calcium channel blocker approved by the FDA as an anticonvulsant for absence seizures.
The companies and academics are working to assess challenges and seek opportunities that could influence T Type Calcium Channel Antagonists R&D. The therapies under development are focused on novel approaches for T Type Calcium Channel Antagonists.
This segment of the T Type Calcium Channel Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
T Type Calcium Channel Antagonists Emerging Drugs
NBI 827104: Neurocrine Biosciences
NBI-827104 is a potent, selective, orally active and brain penetrating T-type calcium channel blocker. Neurocrine Biosciences acquired the exclusive rights to NBI-827104 from Idorsia. The drug is in Phase II clinical studies for essential tremor and Epileptic Encephalopathy with Continuous Spike-and-Wave during Sleep (EE-CSWS). Neurocrine Biosciences has received orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration for NBI-827104 in EE-CSWS.
PRAX-944: Praxis Precision Medicines
PRAX 944 is an oral, small molecule based T-type calcium channel blocker. The drug is in Phase II clinical developmental studies for the treatment of essential tremor. PRAX-944 is suitable for potential development across a wide-range of indications in psychiatry and neurology.
Further product details are provided in the report……..
This segment of the report provides insights about the different T Type Calcium Channel Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 10+ key companies which are developing the T Type Calcium Channel Antagonists. The companies which have their T Type Calcium Channel Antagonists drug candidates in the most advanced stage, i.e. Phase II include, Neurocrine Biosciences.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
T Type Calcium Channel Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses T Type Calcium Channel Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging T Type Calcium Channel Antagonists drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
T Type Calcium Channel Antagonists: Overview
Pipeline Therapeutics
Therapeutic Assessment
T Type Calcium Channel Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
T Type Calcium Channel Antagonists Collaboration Deals
Late Stage Products (Phase III)
Benidipine/telmisartan: Synokem Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
NBI 827104: Neurocrine Biosciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
KBP 5660: Sihuan Pharmaceutical Holdings Group
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
CLX-CNS-04: Cellix Bio
Drug profiles in the detailed report…..
Inactive Products
T Type Calcium Channel Antagonists Key Companies
T Type Calcium Channel Antagonists Key Products
T Type Calcium Channel Antagonists- Unmet Needs
T Type Calcium Channel Antagonists- Market Drivers and Barriers
T Type Calcium Channel Antagonists- Future Perspectives and Conclusion
T Type Calcium Channel Antagonists Analyst Views
T Type Calcium Channel Antagonists Key Companies
Appendix
List of Table
Table 1: Total Products for T Type Calcium Channel Antagonists
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for T Type Calcium Channel Antagonists
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Bial
• Synokem Pharmaceuticals
• Neurocrine Biosciences
• Praxis Precision Medicines
• Sihuan Pharmaceutical Holdings Group
• Cellix Bio
• Maruho
• DermaXon
